- Home
- XBIO vs VEEE Comparison
XBIO vs VEEE Comparison
Compare XBIO & VEEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- VEEE
- Stock Information
- Founded
- XBIO N/A
- VEEE 1994
- Country
- XBIO United States
- VEEE United States
- Employees
- XBIO N/A
- VEEE N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- VEEE Marine Transportation
- Sector
- XBIO Health Care
- VEEE Industrials
- Exchange
- XBIO Nasdaq
- VEEE Nasdaq
- Market Cap
- XBIO 5.8M
- VEEE 6.4M
- IPO Year
- XBIO N/A
- VEEE 2021
- Fundamental
- Price
- XBIO $2.67
- VEEE $0.35
- Analyst Decision
- XBIO Hold
- VEEE
- Analyst Count
- XBIO 1
- VEEE 0
- Target Price
- XBIO N/A
- VEEE N/A
- AVG Volume (30 Days)
- XBIO 6.9K
- VEEE 53.2K
- Earning Date
- XBIO 03-18-2025
- VEEE 03-20-2025
- Dividend Yield
- XBIO N/A
- VEEE N/A
- EPS Growth
- XBIO N/A
- VEEE N/A
- EPS
- XBIO N/A
- VEEE N/A
- Revenue
- XBIO $2,500,284.00
- VEEE $14,388,517.00
- Revenue This Year
- XBIO N/A
- VEEE N/A
- Revenue Next Year
- XBIO $27.78
- VEEE N/A
- P/E Ratio
- XBIO N/A
- VEEE N/A
- Revenue Growth
- XBIO N/A
- VEEE N/A
- 52 Week Low
- XBIO $2.26
- VEEE $0.31
- 52 Week High
- XBIO $5.20
- VEEE $0.99
- Technical
- Relative Strength Index (RSI)
- XBIO 27.60
- VEEE 42.80
- Support Level
- XBIO $3.25
- VEEE $0.32
- Resistance Level
- XBIO $3.43
- VEEE $0.42
- Average True Range (ATR)
- XBIO 0.24
- VEEE 0.03
- MACD
- XBIO -0.08
- VEEE -0.00
- Stochastic Oscillator
- XBIO 25.63
- VEEE 30.00
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About VEEE Twin Vee PowerCats Co.
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power catamaran boats to use for fishing, diving and water skiing and commercial activities including transportation, eco-tours, fishing, and diving expeditions. Its revenue is derived from the sale of boats, motors, and trailers to its independent dealers. It has organized its business into three operating segments: The gas-powered boat segment, which manufactures and distributes gas-powered boats; The electric-powered boat segment, which is developing fully electric boats, through its controlling interest subsidiary, and its franchise segment, which is developing a standard product offering and will be selling franchises across the United States through its wholly-owned subsidiary.